MAPT and Alzheimer disease: Interestingly, DTI alterations are larger in FTD patients than in AD patients [11, 13–16], while preclinical alterations in APOE4 carriers [39, 44–51] are more widespread than in MAPT/GRN mutation carriers [32, 33].